Connect to share and comment

Drugmaker Merck replacing CFO Kellogg with Baxter International executive Davis in April

WHITEHOUSE STATION, N.J. - Drugmaker Merck Merck, based in Whitehouse Station, N.J., said Thursday that Robert M. Davis will become CFO on April 23. Davis, 47, also will oversee corporate strategy and business development. Currently he's president of Baxter International Inc.'s medical products business, where he managed the integration of its worldwide kidney treatment and medication delivery businesses into one division. Davis previously worked at drugmaker Eli Lilly and Co., then joined Baxter in 2004 as treasurer and served as CFO from 2006 through May 2010.

Merck KGaA names new heads of lab equipment, OTC drugs units

FRANKFURT (Reuters) - Diversified healthcare and chemicals group Merck KGaA said the head of its Consumer Health unit, Udit Batra, would become chief executive of its much larger laboratory and biotech equipment unit Merck Millipore. Batra will succeed Robert Yates, who has decided to leave the German company to take on a new job outside of Merck, it said on Tuesday.

Exclusive: Bayer, Novartis, others eye Merck's consumer health unit - sources

By Olivia Oran, Soyoung Kim and Anjuli Davies NEW YORK/LONDON (Reuters) - A handful of consumer and healthcare companies including Bayer AG and Novartis are exploring a deal for Merck & Co Inc's consumer healthcare business, as they seek to gain scale in a fragmented industry, according to several people familiar with the matter.

Merck KGaA extends offer for AZ Electronic

German chemicals and pharmaceuticals group Merck KGaA said on Thursday it was extending its offer to take over British group AZ Electronic Materials until February 18. The group has already extended the cash offer -- of 403.5 pence (4.85 euros, $6.57) per share -- once before until Wednesday, by which time Merck had amassed a stake of 56.48 percent in the British firm. Merck said the minimum acceptance level, however, is 95 percent. The friendly takeover bid values AZ Electronic at a total 1.9 billion euros, including the assumption of 238 million euros of debt.

Merck KGaA extends offer for AZ Electronic

German chemicals and pharmaceuticals group Merck KGaA said on Thursday it was extending its offer to take over British group AZ Electronic Materials until February 18. The group has already extended the cash offer -- of 403.5 pence (4.85 euros, $6.57) per share -- once before until Wednesday, by which time Merck had amassed a stake of 56.48 percent in the British firm. Merck said the minimum acceptance level, however, is 95 percent. The friendly takeover bid values AZ Electronic at a total 1.9 billion euros, including the assumption of 238 million euros of debt.

Merck results flag, but cancer-drug deals lift shares

By Ransdell Pierson (Reuters) - Merck & Co Inc's quarterly profit and sales just missed expectations as its medicines faced competition from cheaper generics, but the company announced potentially lucrative new cancer-drug partnerships with rival U.S. drugmakers. For the full year, Merck expected to earn $3.35 to $3.53 per share, excluding special items. The average analyst estimate was $3.48 per share.

Drugmaker Merck's Q4 profit, sales fall due to generic competition, unfavourable exchange rates

Merck Results just missed Wall Street expectations, and even though Merck said 2014 will be a "trough year" for revenue, shares briefly hit a six-year high of $55.20. That's because the world's third-biggest drugmaker separately announced new, potentially lucrative alliances. Merck will collaborate with three other drugmakers to test its hot experimental cancer drug, called MK-3475, in combination with theirs. It's in a new class of cancer medicines meant to restore the immune system's natural ability to spot and target cancer cells.

Amgen cholesterol drug meets goal of third late stage trial

(Reuters) - A cholesterol fighter developed by Amgen Inc from a new class of medicines succeeded in significantly lowering levels of "bad" LDL cholesterol in a late stage trial in patients unable to tolerate statin drugs, the company said on Thursday. The results marked the third successful Phase III test of the drug evolocumab reported by Amgen in recent months - this one in a patient population among the most in need of alternative therapies.

Merck recalls all Liptruzet cholesterol pills over package defect that could cut effectiveness

TRENTON, N.J. - Drugmaker Merck Merck said the recall covers all four dose strengths and every batch distributed since Liptruzet was launched last May. Both active ingredients in the drug remain available separately, though. Merck, the world's third-biggest drugmaker, said some of the foil pouches holding the pills may allow air and moisture inside. The company said there's a remote chance that could decrease the drug's effectiveness or otherwise change its properties, but that the recall is not due to any reports of patients being harmed.

Merck recalls all supply of combo cholesterol drug Liptruzet, no reports of patient harm

WHITEHOUSE STATION, N.J. - Drugmaker Merck Merck says the recall covers all four dose strengths and every batch distributed since Liptruzet (LIP'-trew-zet) was launched last May. Merck, the world's third-biggest drugmaker, says some of the foil pouches holding the pills may allow air and moisture inside. Merck says there's a remote chance that could decrease the drug's effectiveness or otherwise change its properties, but that the recall is not due to any reports of patients being harmed.
Syndicate content